At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Electrocardiogram (diagnostic test), Transthoracic echocardiogram (diagnostic test), Right heart catheter (diagnostic test)
- How long the study runs
- Study runs about 27 months (dates as stated)
- About the drug or intervention
- Electrocardiogram — diagnostic test: Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart · Transthoracic echocardiogram — diagnostic test: Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound · Right heart catheter — diagnostic test: Minimally invasive cardiac chamber pressure measurement using balloon catheterisation
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 2,500
- Started
- 2024-09-06
- Last checked
- 2025-06
Plain English Summary
What is this study?
- • Testing a new treatment for pulmonary hypertension
- • Clinical study - 2,500 participants
- • The goal of this observational study is to assess the efficacy that the addition of novel markers cardiac function, particularly of right ventricular (RV) function in echocardiography, and ECG have in detecting pulmonary hypertension
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with pulmonary hypertension
Where?
- • Bath - Royal United Hospital NHS Foundation Trust
- • Glasgow - Golden Jubilee Hospital
- • Sheffield - Sheffield Teaching Hospitals NHS Foundation Trust
- • Cambridge - Royal Papworth Hospital
- • +1 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The goal of this observational study is to assess the efficacy that the addition of novel markers cardiac function, particularly of right ventricular (RV) function in echocardiography, and ECG have in detecting pulmonary hypertension. The main questions it aims to answer are: Can novel markers in ECG and echocardiography suggest the presence of PH? Can existing screening guidelines be improved with the addition of these markers?
More detail
Pulmonary Hypertension (PH) is a condition caused by high blood pressure in the blood vessels that carry blood to the lungs. It can cause severe breathlessness and failure of the right side of the heart. Sadly it is often fatal. PH can be caused by a number of different conditions and life expectancy varies with the underlying cause, ranging from months to years. For some subtypes of PH, effective treatments exist which can significantly improve life expectancy and quality of life. Accurate tools for the assessment of PH are therefore essential, so that we can better understand and predict life expectancy and so that life-saving medications can be started earlier. Once doctors suspect that somebody has PH, they refer them to a specialist PH centre for assessment and a procedure called right heart catheterisation (RHC), which will confirm the diagnosis. However, evidence for the suspicion of PH is frequently overlooked, leading to an average delay to diagnosis from onset of symptoms of two years. This late presentation negatively impacts survival for these patients and prevents them promptly starting the effective treatments which are available. An electrocardiogram (ECG) is a recording of the heart's electrical signals, printed in waveforms. It is a painless, low-cost, and readily-available test used in PH assessment. Echocardiography (echo) is a quick, safe and well-tolerated test often requested to investigate breathless patients and can provide useful information about the suspicion of PH. Echo has however been shown to lack accuracy in milder forms of the disease. It has been hypothesised that subtle markers of right ventricular function by echo, such as free wall strain (RVFWS) begin to deteriorate before the more established findings. A large, cross-population study of ECG features and echo markers such as RVFWS both in isolation and in combination, in patients referred for PH assessment may help identify these markers, and improve detection of the disease.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Patients 18+ who have undergone TTE, ECG and RHC as part of their clinical care
Who cannot take part
- ✗Patients \<18 years old
- ✗Known or suspected congenital heart disease
- ✗Patient has opted-out of allowing their data to be used for research and planning (via the national data opt-out...
See the full criteria
Where Is This Study? (5 UK sites)
Royal United Hospital NHS Foundation Trust
Bath BA1 3NG, United Kingdom
Golden Jubilee Hospital
Glasgow G81 4DY, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield S10 2JF, United Kingdom
Royal Papworth Hospital
Cambridge CB2 0AY, United Kingdom
Royal Free NHS Foundation Trust
London NW3 2QG, United Kingdom
How to Get in Touch
Christopher Wild
Sponsor contactCONTACT
Jane Carter
Sponsor contactCONTACT
